Amylyx Pharmaceuticals, Inc. Common Stock AMLX
Analyst Ratings
- Consensus
- Buy — 7 Buy · 0 Hold · 0 Sell (7 analysts)
- Avg. Price Target
- $38.86 (+31.8% upside)
Key Stats
- Today's Range
- $29.47 – $30.70
- 50-Day Range
- $16.52 – $41.14
- 52-Week Range
- $8.47 – $41.14
- Volume
- 1.29 million shs
- Average Volume
- 3.03 million shs
- Market Cap
- $3.76 billion
- P/E Ratio
- —
- Dividend Yield
- 5.69%
Valuation
- P/E Ratio
- —
- Price / Book
- 15.74
- Price / Sales
- —
Dividend
- Dividend Yield
- 5.69%
- Annual Dividend
- $1.68
- Payout Ratio
- —
- Ex-Dividend Date
- 2018-03-28
Short Interest
- Short Interest
- 0.00%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- —
- Net Income
- $-152,092,000
- Net Margin
- —
- Return on Equity
- -63.59%
- Debt-to-Equity
- —
About Amylyx Pharmaceuticals, Inc. Common Stock
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
Related Stocks
Compare head-to-head: AMLX vs LLY·AMLX vs JNJ·AMLX vs ABBV·AMLX vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.